Volrustomig

DB18893InvestigationalProtein Based Therapies

Volrustomig is under investigation in clinical trial NCT06097728 (MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma).

Mechanism: Pharmacologically active on Cytotoxic T-lymphocyte protein 4 and Programmed cell death protein 1
Curator reviewed
Code names: MEDI-5752

Resolves to

Compound

UNIIK96EGJ218NCAS2407760-40-9

Targets

P16410CTLA4Q15116PDCD1

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

26Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Volrustomig, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account